RevolutionLogo.png
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
01 nov. 2022 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
RevolutionLogo.png
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
22 sept. 2022 07h00 HE | Revolution Medicines, Inc.
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to...
Blue-Star-Logo-1024x321.png
Blue Star Foods Extends Multi-Year Supply Relationship with Avendra
19 sept. 2022 08h00 HE | Blue Star Foods Corp.
Solidifies Relationship with North America’s Leading Hospitality Procurement Services Provider Miami, FL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,”...
Blue-Star-Logo-1024x321.png
Blue Star Foods Extends Multi-Year Supply Relationship with Sysco Corporation
13 sept. 2022 08h00 HE | Blue Star Foods Corp.
Miami, FL, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG)...
RevolutionLogo.png
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
01 sept. 2022 16h05 HE | Revolution Medicines, Inc.
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE...
RevolutionLogo.png
Revolution Medicines to Participate in Upcoming Investor Conferences
31 août 2022 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
NCRA_Logo.jpg
Nocera, Inc. Announces Second Quarter 2022 Financial Results
23 août 2022 08h00 HE | Nocera, Inc
TAIPEI CITY, Taiwan, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Nocera, Inc. (NASDAQ: NCRA) (“Nocera” or the “Company”), a fully integrated sustainable seafood company with a focus on manufacturing and...
Blue-Star-Logo-1024x321.png
Blue Star Foods Reports Revenue Growth of 79% for First Half of 2022
16 août 2022 07h30 HE | Blue Star Foods Corp.
Highlighted by Initial $0.5 Million Revenue from Soft-Shell Crab RAS Miami, FL, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ:...
NCRA_Logo.jpg
Nocera, Inc. Announces Closing of $6.58 Million Underwritten Public Offering
15 août 2022 12h41 HE | Nocera, Inc
TAIPEI CITY, Taiwan, Aug. 15, 2022 (GLOBE NEWSWIRE) --  Nocera, Inc. (NASDAQ: NCRA) (“Nocera” or “the Company”), a fully integrated sustainable seafood company with a focus on manufacturing and...
NCRA_Logo.jpg
Nocera Announces Pricing of $6.58 Million Public Offering, Nasdaq Listing and Reverse Stock Split
10 août 2022 18h45 HE | Nocera, Inc
TAIPEI CITY, Taiwan, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Nocera, Inc. (OTC: NCRA; NASDAQ: NCRA) (“Nocera” or “the Company”), a fully integrated sustainable seafood company with a focus on...